Outlook

Filter By:

  • A more open approach to combating tropical diseases may help to overcome a pharmaceutical market failure.

    • Lucas Laursen
    Outlook
  • In 2006, pharmaceutical innovation consultant Bernard Munos helped to launch a lively public discussion about how open innovation can bring novel drugs to market with his paper 'Can opensource R&D reinvigorate drug research? He tells Nature how things have changed since then.

    • Eric Bender
    Outlook
  • A growing appreciation that cooperation and competition can coexist is transforming the life-sciences innovation landscape. Development was once shrouded in secrecy, but now organizations are coming together.

    • David Holmes
    Outlook
  • Open initiatives are promising, but we have much further to go if research data are to be as publicly accessible as they should be, says Aled Edwards.

    • Aled Edwards
    Outlook
  • Drug discovery is time-consuming and full of blind alleys. Pharmaceutical rivals are cooperating in the early stages to accelerate and improve the efficiency of the process.

    • Neil Savage
    Outlook
  • In a pioneering move, the compound JQ1 was released to the community for free. The impact that this has had on research and development is slowly coming into focus.

    • Andrew R. Scott
    Outlook
  • Advocates say that open science will be good for innovation. One neuroscience institute plans to put that to the test.

    • Brian Owens
    Outlook
  • University research powers innovation and economic development. Countries with intensive research and development (R&D) programmes differ in their approach to turning lab studies into commercial enterprises. By Alla Katsnelson, infographic by Mohamed Ashour.

    • Alla Katsnelson
    Outlook
  • Austrian social scientist Helga Nowotny was president of the European Research Council between 2010 and 2013. Now a professor emerita of ETH Zurich and author of The Cunning of Uncertainty (Polity, 2015), Nowotny discusses the growing pressure to capitalize on academic research, and how countries can get it right in the absence of a universal recipe.

    • Chelsea Wald
    Outlook
  • After starting one of Germany's first biotech companies, biochemist Horst Domdey co-founded BioM, a non-profit organization that has managed and developed Munich's biotechnology cluster since 1997. He talks to Nature about nurturing the entrepreneurial spirit in “a country of competitions”.

    • Chelsea Wald
    Outlook
  • A broader understanding of 'impact' could help governments to measure the diverse benefits of their investment in research.

    • Michael Eisenstein
    Outlook
  • When it comes to translating its own research into practical applications, China falls short. A forum in Shanghai put the spotlight on ambitious plans to accelerate the process.

    • Nicky Phillips
    Outlook
  • The value that Australia places on publication quality over quantity has elevated it into the top echelon of science. Can it now improve its flagging track record in commercialization?

    • Bianca Nogrady
    Outlook
  • Universities aid entrepreneurs by helping them to turn their research into companies. In return, universities can reap financial benefits.

    • Neil Savage
    Outlook
  • For the past decade, venture philanthropists have been working to propel promising therapies and vaccines into the clinic, with some success.

    • Cassandra Willyard
    Outlook